marked.bio

CLDN18.2 ADC · ADC

LM-302

9 active trials across 2 of our biomarkers, targeting Claudin 18.2. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
Claudin 18.2 expression 9 11 Phase 3
MSI-H / dMMR 0 1 –

Sponsors

Industry sponsors leading active biomarker-selected trials of LM-302.

  1. LaNova Medicines Zhejiang 2
  2. Shanghai Chia Tai Tianqing Pharmaceutical Technology Development 1

Trials

9 of 11 trials shown

  1. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

    Recruiting Phase 3 Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Started 2026Primary completion 2028-10 NCT07385703

    LM-302tislelizumaboxaliplatincapecitabine

    After confirmation by the central laboratory, tumor tissue with positive CLDN18.2 expression is defined as ≥25% tumor cell membrane staining intensity 2+ \& 3+.

    Claudin 18.2 expressionAdenocarcinoma

  2. LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

    Active, not recruiting Phase 3 LaNova Medicines Zhejiang Started 2024Primary completion 2026-11 NCT06351020

    LM-302apatinibirinotecan

    Centrally confirmed CLDN18.2-positive

    Claudin 18.2 expressionLocally Advanced or Metastatic GC and GCJ Adenocarcinoma

  3. Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma

    Recruiting Phase 2 Ruijin Hospital Started 2026Primary completion 2028-04 NCT07569068

    tislelizumabLM-302oxaliplatin

    Claudin 18.2 positive (≥25% of tumor cells showing moderate-to-strong membrane staining);

    Claudin 18.2 expressionGastric or Esophagogastric Junction Adenocarcinoma

  4. LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study

    Recruiting Phase 2 Ruijin Hospital Started 2026Primary completion 2028-04 NCT07556640

    LM-302paclitaxelcadonilimab

    Claudin 18.2 positive (≥ 25%, moderate to strong staining);

    Claudin 18.2 expressionGastric Cancer Stage IV, Peritoneal Metastases From Gastric Cancer, Gastric or Esophagogastric Junction Adenocarcinoma

  5. Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis

    Recruiting Phase 2 Ruijin Hospital Started 2025Primary completion 2027-01 NCT06519591

    cadonilimabLM-302paclitaxel

    Claudin 18.2 positive (≥ 25%, and the proportion of positive cells greater than 50% of the cases accou…

    Claudin 18.2 expressionGastric Cancer Stage IV, Peritoneal Metastases

  6. Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer

    Not yet recruiting Phase 2 Shanghai Zhongshan Hospital Started 2025Primary completion 2026-08 NCT07108504

    gemcitabineLM-302

    CLDN18.2 positivity defined as: Moderate-to-high staining intensity (2+\~3+) in ≥50% of tumor cell…

    Claudin 18.2 expressionPancreatic Cancer, Chemotherapy Effect

  7. The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

    Recruiting Phase 2 Shanghai Zhongshan Hospital Started 2024Primary completion 2025-07 NCT06587425

    LM-302capecitabinecadonilimab

    CLDN18.2 positivity: Provide sufficient tissue markers for Claudin18.2 immunohistochemistry testin…

    Claudin 18.2 expressionStatus may be outdated, last updated 2024-09-19Gastric or Gastroesophageal Junction Adenocarcinoma

  8. A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

    Recruiting Phase 2 LaNova Medicines Zhejiang Started 2023Primary completion 2031-08 NCT05934331

    LM-302toripalimabcapecitabineTegafur, Gimeracil and Oteracil Potassium Capsulesnivolumabapatinibgemcitabinetislelizumabanlotinibbenmelstobart

    CLDN18.2-positive subjects.

    Claudin 18.2 expressionMalignant Neoplasms of Digestive Organs

  9. Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody

    Active, not recruiting Phase 1/2 Shanghai Zhongshan Hospital Started 2023Primary completion 2026-05 NCT05994001

    cardonilizumabLM-302

    …histologically confirmed, and sufficient tissue specimens are provided for PD-L1, CTLA-4, Claudin18.2 immunohistochemistry and exon sequencing.

    Claudin 18.2 expressionBiliary Tract Cancer, Candonilimab, Claudin 18.2